Shimada H, Himeno K, Michimoto T, Tanada S, Ikeuchi M, Suwa M, Ono Y, Hoshino T, Takashima E, Ohkura K
Department of Obstetrics and Gynecology, Kobe City General Hospital.
Nihon Sanka Fujinka Gakkai Zasshi. 1990 Jul;42(7):705-10.
We studied the effect of vitamin K(MK-4) on the prevention of vitamin K deficiency in the early neonatal period. MK-4 (20 mg/day) was given orally for 1-7 days to 183 pregnant women at 37-39 weeks gestation. In the MK-4 treated group, there were no cases of melena neonatorum but there were 9 cases in the untreated group (9/757, 1.2%). To investigate the influence of MK-4 administration on liver function and the VK dependent coagulation system, maternal and umbilical venous blood were taken to measure T-Bil, GOT, GPT, gamma-GTP, LDH, and II, VII, X activity and HPT. There was no significant difference between these values in MK-treated and untreated groups. MK-4 concentrations were measured in the maternal and umbilical venous blood of 68 subjects. The level of MK-4 in umbilical venous blood was less than 0.1 ng/ml in 17 of 21 subjects not treated with MK-4 but it was over 0.1 ng/ml in 30 of 47 MK-4 treated subjects. However, no MK-4 was detected in 6 of 8 subjects who were treated for 1 day. The level of MK-4 in maternal blood was less than 0.1 ng/ml in 12 of 21 untreated subjects but it was 0.19-92.6 ng/ml in all of the 47 MK-4 treated subjects. The mean MK-4 concentration in cord blood as a percentage of that in maternal blood was 17.9%. These findings indicate that MK-4 is effectively transported from maternal to fetal blood through the placenta and its administration to pregnant women is useful in preventing melena neonatorum.
我们研究了维生素K(甲萘醌-4,MK-4)对预防新生儿早期维生素K缺乏的作用。在妊娠37-39周时,对183名孕妇口服给予MK-4(20毫克/天),持续1-7天。在MK-4治疗组中,未出现新生儿黑便病例,但未治疗组中有9例(9/757,1.2%)。为了研究MK-4给药对肝功能和维生素K依赖凝血系统的影响,采集了母体和脐静脉血以检测总胆红素(T-Bil)、谷草转氨酶(GOT)、谷丙转氨酶(GPT)、γ-谷氨酰转肽酶(gamma-GTP)、乳酸脱氢酶(LDH)以及凝血因子II、VII、X活性和肝促凝血酶原激酶试验(HPT)。MK-4治疗组和未治疗组的这些值之间无显著差异。对68名受试者的母体和脐静脉血进行了MK-4浓度测定。在21名未接受MK-4治疗的受试者中,有17名脐静脉血中MK-4水平低于0.1纳克/毫升,但在47名接受MK-4治疗的受试者中,有30名脐静脉血中MK-4水平超过0.1纳克/毫升。然而,在接受1天治疗的8名受试者中,有6名未检测到MK-4。在21名未治疗受试者中,有12名母体血中MK-4水平低于0.1纳克/毫升,但在所有47名接受MK-4治疗的受试者中,母体血中MK-4水平为0.19-92.6纳克/毫升。脐血中MK-4浓度占母体血中MK-4浓度的平均百分比为17.9%。这些发现表明,MK-4可通过胎盘从母体有效转运至胎儿血液,对孕妇给药有助于预防新生儿黑便。